3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
3
Wound Infection
2
Infections
2
Surgical Wound Infection
1
Laryngeal Neoplasms
1
Bone Neoplasms
1
Interventions
Ibandronic Acid
5
Zoledronic Acid
3
Denosumab
3
pembrolizumab
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Nivolumab
2
Methods
2
Interviews as Topic
2
Injections
2
Curettage
2
selinexor
1
saracatinib
1
ridaforolimus
1
radium Ra 223 dichloride
1
pegfilgrastim
1
olaparib
1
montanide ISA 51
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
endostar protein
1
cc-486
1
angiotensin I (1-7)
1
Vincristine
1
Transplantation, Homologous
1
Transplantation, Autologous
1
Transcranial Direct Current Stimulation
1
Trabectedin
1
Tomography, Spiral Computed
1
TES
1
Surveys and Questionnaires
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Bone Neoplasms
×
Cefazolin
×
Clear all
NCT01479283
2021-03-11
PARITY
McMaster University
Phase 3
Completed
602 enrolled